296 related articles for article (PubMed ID: 24289617)
1. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
[TBL] [Abstract][Full Text] [Related]
2. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
3. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
5. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients.
Dehghani M; Keshavarz P; Talei A; Akrami M; Tahmasebi S; Safaie A; Ghanbari M
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3027-3032. PubMed ID: 33112563
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
Doval DC; Sharma A; Sinha R; Kumar K; Dewan AK; Chaturvedi H; Batra U; Talwar V; Gupta SK; Singh S; Bhole V; Mehta A
Asian Pac J Cancer Prev; 2015; 16(12):4959-64. PubMed ID: 26163622
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
14. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
[TBL] [Abstract][Full Text] [Related]
16. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
18. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes.
Yang Q; Liu HY; Liu D; Song YQ
Asian Pac J Cancer Prev; 2015; 16(8):3229-32. PubMed ID: 25921124
[TBL] [Abstract][Full Text] [Related]
20. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
